David Chilton Mitchell - Net Worth and Insider Trading

David Chilton Mitchell Net Worth

The estimated net worth of David Chilton Mitchell is at least $904 dollars as of 2024-11-13. David Chilton Mitchell is the VP Global Regulatory & Quality of Neoleukin Therapeutics Inc and owns about 259 shares of Neoleukin Therapeutics Inc (NLTX) stock worth over $904. Details can be seen in David Chilton Mitchell's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that David Chilton Mitchell has not made any transactions after 2015-08-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of David Chilton Mitchell

To

David Chilton Mitchell Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, David Chilton Mitchell owns 1 companies in total, including Neoleukin Therapeutics Inc (NLTX) .

Click here to see the complete history of David Chilton Mitchell’s form 4 insider trades.

Insider Ownership Summary of David Chilton Mitchell

Ticker Comapny Transaction Date Type of Owner
NLTX Neoleukin Therapeutics Inc 2015-08-24 VP Global Regulatory & Quality

David Chilton Mitchell Latest Holdings Summary

David Chilton Mitchell currently owns a total of 1 stock. David Chilton Mitchell owns 259 shares of Neoleukin Therapeutics Inc (NLTX) as of August 24, 2015, with a value of $904.

Latest Holdings of David Chilton Mitchell

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NLTX Neoleukin Therapeutics Inc 2015-08-24 259 3.49 904

Holding Weightings of David Chilton Mitchell


David Chilton Mitchell Form 4 Trading Tracker

According to the SEC Form 4 filings, David Chilton Mitchell has made a total of 0 transactions in Neoleukin Therapeutics Inc (NLTX) over the past 5 years. The most-recent trade in Neoleukin Therapeutics Inc is the acquisition of 179 shares on August 24, 2015, which cost David Chilton Mitchell around $63,671.

Insider Trading History of David Chilton Mitchell

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

David Chilton Mitchell Trading Performance

GuruFocus tracks the stock performance after each of David Chilton Mitchell's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David Chilton Mitchell is -35.19%. GuruFocus also compares David Chilton Mitchell's trading performance to market benchmark return within the same time period. The performance of stocks bought by David Chilton Mitchell within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how David Chilton Mitchell's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of David Chilton Mitchell

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -7.18 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.26 LIMIT LIMIT LIMIT LIMIT LIMIT

David Chilton Mitchell Ownership Network

Ownership Network List of David Chilton Mitchell

No Data

Ownership Network Relation of David Chilton Mitchell

Insider Network Chart

David Chilton Mitchell Owned Company Details

What does Neoleukin Therapeutics Inc do?

Who are the key executives at Neoleukin Therapeutics Inc?

David Chilton Mitchell is the VP Global Regulatory & Quality of Neoleukin Therapeutics Inc. Other key executives at Neoleukin Therapeutics Inc include 10 percent owner Baker Bros. Advisors Lp , Principal Accounting Officer Sean Michael Smith , and Chief Medical Officer Priti Patel .

Neoleukin Therapeutics Inc (NLTX) Insider Trades Summary

Over the past 18 months, David Chilton Mitchell made no insider transaction in Neoleukin Therapeutics Inc (NLTX). Other recent insider transactions involving Neoleukin Therapeutics Inc (NLTX) include a net purchase of 2,285,342 shares made by Baker Bros. Advisors Lp , and a net sale of 1,323 shares made by Sean Michael Smith .

In summary, during the past 3 months, insiders sold 0 shares of Neoleukin Therapeutics Inc (NLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 66 shares of Neoleukin Therapeutics Inc (NLTX) were sold and 114,267 shares were bought by its insiders, resulting in a net purchase of 114,201 shares.

Neoleukin Therapeutics Inc (NLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Neoleukin Therapeutics Inc Insider Transactions

No Available Data

David Chilton Mitchell Mailing Address

Above is the net worth, insider trading, and ownership report for David Chilton Mitchell. You might contact David Chilton Mitchell via mailing address: C/o Aquinox Pharmaceuticals, Inc., 450 - 887 Great Northern Way, Vancouver A1 V5t 4t5.